Search Medical Condition
Please enter condition
Please choose location

San Vicente del Raspeig, Spain Clinical Trials

A listing of San Vicente del Raspeig, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (113) clinical trials

Aneuploidies in Embryos and Spermatozoa From Patients With Y-chromosome Microdeletions

Nowadays, Y-chromosome microdeletions are one of the most common causes of male infertility. With a frequency of 8-20% in non-obstructive azoospermic men and 3-14% in severe oligozoospermic men, is the most usual chromosome anomaly associated with failure in sperm production, although the frequency seems to change due to differences in ...

Phase N/A

4.18 miles

Learn More »

Human Sperm Markers of Cryodamage Resistance

Nested cases and controls design, with donor sperm samples frozen under conventional protocols, categorized depending on their good (GSR, n=20) (less than 20% motility decrease) or bad (BSR, n=20) (more than 20% motility decrease) survival rates. Sperm mRNA was extracted using Trizol protocol, suspended in diethylpyrocarbonate (DEPC)-treated water and frozen ...

Phase N/A

4.18 miles

Learn More »

Study for the Evaluation of "MitoScore" Marker in the Diagnosis of Embryo Viability in Euploids Embryos

The number of mitochondrial DNA copies (mtDNA) of a chromosomally normal embryo is related to a state of energy, which affects the ability of the embryo to implant in the maternal uterus. There is a decrease in the rate of implantation in euploid embryos containing a high number of mtDNA ...

Phase N/A

4.18 miles

Learn More »

The ERA Test as a Diagnostic Guide for Personalized Embryo Transfer

This project seeks to investigate differences in implantation (IR), pregnancy (PR), ongoing pregnancy (OP) rates and delivery among women undergoing transfer at the blastocyst stage in their first IVF/ICSI cycle comparing the normal practice of same-cycle embryo transfer in a fresh cycle (ET) versus deferred embryo transfer (DET) versus personalized ...

Phase N/A

4.18 miles

Learn More »

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or VKA for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a ...

Phase

4.18 miles

Learn More »

Global Non-interventional Heart Failure Disease Registry

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for ...

Phase N/A

4.18 miles

Learn More »

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

This study has two arms: Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment. Arm 2 (INC280 + nivolumab) is open and enrolling as planned.

Phase

4.18 miles

Learn More »

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease

The drug being tested in this study is called vedolizumab SC. Vedolizumab SC is being tested to treat people who have moderate to severely active CD. This study will look at clinical remission, as well as enhanced clinical response and corticosteroid-free remission in participants with CD who receive vedolizumab SC ...

Phase

4.18 miles

Learn More »

Vedolizumab Subcutaneous Long-Term Open-Label Extension Study

The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC). Vedolizumab SC is being tested to assess its long-term safety and effectiveness in treating participants with UC or CD. This study will look at the long-term side effects and response/remission of UC and CD in participants who ...

Phase

4.18 miles

Learn More »

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

Double blind placebo-controlled study. The subjects will receive medication during 4 months.

Phase

4.18 miles

Learn More »